Abstract:All medical device companies require FDA 510(K) clearance before they can market their products. Using this external certification as a natural experiment, this paper analyzes the dynamics of the syndicate formation process of venture capital firms as well as the certification role that venture capitalists may play. Our results suggest that FDA 510(k) clearance does serve as an outside certification reducing uncertainty that leads to a larger amount of capital flow into the company from a greater number of investors after the approval. Pre-approval syndicate formation seems to be driven by a search for second-opinion with greater likelihood of IPO exit, while post-approval syndicate formation seems to be driven by the need for capital on lower risk investments that also have lower chance of an IPO exit. We test several non-mutually exclusive hypotheses on project selection, second opinion, and diversification and find support for our hypotheses. Younger VC firms are more likely to invest in start-ups pre-certification and start-up companies that can secure funds pre-certification are more likely to make it to IPO.2